REGN vs VRTX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
REGN · Regeneron Pharmaceuticals$904.35 ▲ 0.16%
VRTX · Vertex Pharmaceuticals$547.09 ▲ 0.85%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- REGN +38.8%
- VRTX +29.9%
Head to head
| Metric | REGN | VRTX |
|---|---|---|
| Price | $904.35 | $547.09 |
| Change today | ▲ 0.16% | ▲ 0.85% |
| Market cap | $93.55B | $138.71B |
| Return, 3 months | +12.0% | +4.4% |
| Return, year to date | +17.6% | +20.7% |
| Return, 1 year | +38.2% | +33.6% |
| P/E (TTM) | 20.0 | 35.2 |
| P/B | 2.8 | 6.6 |
| P/E percentile vs own 5y | 81st | 97th |
| Dividend yield | 0.41% | – |
| Revenue growth (YoY, latest qtr) | +36.3% | +12.5% |
| Net profit growth (YoY) | +33.5% | +6.5% |
| Gross margin | 85.8% | 86.0% |
| Operating margin | 30.4% | 37.9% |
| Net margin | 28.5% | 35.0% |
| Return on equity | 14.9% | 23.5% |
| Analyst target vs. price | +6.1% | +14.4% |
| Analyst buy share | 70% | 95% |
| RSI (14) | 63 | 58 |
| 30-day volatility | 48.7% | 32.0% |
| Max drawdown, 1 year | -25.9% | -15.2% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- VRTX is the largest of the group by market value.
- REGN has returned the most over the past year.
- REGN carries the lowest trailing P/E.
- REGN is growing revenue fastest.
- VRTX keeps the most profit per dollar of sales.
- VRTX has been the calmest stock over the last 30 days.